Cancer-associated fibroblast activation machinery (CAF activation machinery)

The cancer-associated fibroblast (CAF) activation machinery encompasses the complex signaling networks and cellular processes that drive the transformation of quiescent fibroblasts into activated, pro-tumorigenic CAFs (NIH, 2024; MDPI, 2024). This activation is typically triggered by factors within the tumor microenvironment, including transforming growth factor-beta (TGF-beta), platelet-derived growth factor (PDGF), and various inflammatory cytokines like IL-6 (NIH, 2024; ResearchGate, 2020). Once activated, these cells undergo significant phenotypic changes, characterized by the expression of markers such as fibroblast activation protein (FAP) and alpha-smooth muscle actin (alpha-SMA) (NIH, 2024; AACR, 2024). CAFs play a critical role in cancer progression by remodeling the extracellular matrix, promoting angiogenesis, and creating an immunosuppressive environment that shields tumor cells from the immune system (NIH, 2024; MDPI, 2024). Therapeutic targeting of the CAF activation machinery involves strategies such as inhibiting key signaling pathways, depleting specific CAF subsets, or reprogramming them back to a quiescent state (NIH, 2024; AACR, 2024). Despite the potential of these therapies, a major challenge lies in the inherent heterogeneity of CAFs, as some subpopulations may actually possess tumor-restraining properties (NIH, 2024; ResearchGate, 2020). Furthermore, because fibroblasts are essential for normal tissue homeostasis and wound healing, systemic inhibition of their activation machinery carries risks of impaired repair and off-target toxicity (NIH, 2024).

Other names

CAF activation pathwayFibroblast-to-CAF transitionMyofibroblastic differentiation in cancerCAF reprogramming machinery

Inhibition of signaling pathways (TGF-beta, PDGF, FGF, IL-6) that drive the transition of quiescent fibroblasts into activated CAFs; depletion of activated CAF populations (e.g., via FAP-targeted CAR-T or antibody-drug conjugates); or reprogramming of CAFs to a quiescent or tumor-suppressive state (NIH, 2024; AACR, 2024).